- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01475851
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
June 18, 2015 updated by: GlaxoSmithKline
A Multi-center, Open-label Study of GSK548470 (Tenofovir Disoproxil Fumarate) in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, open-label study in Japanese patients with compensated chronic hepatitis B with poor response to other drugs in order to evaluate the efficacy and safety of GSK548470 administered at a dose of 300 mg once daily.
The target sample size is set at 32 subjects.
The primary objective is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in subjects with compensated chronic hepatitis B with poor response to other drugs.
The secondary objective is to evaluate the long-term efficacy and safety of once-daily treatment with GSK548470 300 mg.To evaluate the efficacy and safety of GSK548470 in the study, subjects receiving a combination of lamivudine (LAM) and adefovir pivoxil (ADV) will be switched to a combination of LAM and GSK548470, while subjects on entecavir hydrate (ETV) with or without ADV will be switched to a combination of ETV and GSK548470.
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aichi, Japan, 467-8602
- GSK Investigational Site
-
Aichi, Japan, 466-8560
- GSK Investigational Site
-
Chiba, Japan, 260-8677
- GSK Investigational Site
-
Fukuoka, Japan, 803-8505
- GSK Investigational Site
-
Hiroshima, Japan, 734-8551
- GSK Investigational Site
-
Hokkaido, Japan, 060-0033
- GSK Investigational Site
-
Kagoshima, Japan, 890-8520
- GSK Investigational Site
-
Kanagawa, Japan, 213-8587
- GSK Investigational Site
-
Miyagi, Japan, 980-8574
- GSK Investigational Site
-
Tokyo, Japan, 180-8610
- GSK Investigational Site
-
Tokyo, Japan, 105-8470
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 69 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The ability to understand and sign a written informed consent form
- 16 to 69 years of age at the time of informed consent
- Females of childbearing potential must have a negative pregnancy test and agree to avoidance of pregnancy
- Subject must show QTc <450 millisecond (msec) or <480msec with Bundle Branch Block
- Chronic HBV infection, defined as positive serum HBsAg for at least 6 month
- Subjects currently treated with LAM/ADV, ETV or ETV/ADV for greater than 24 weeks
- Chronic hepatitis B ; HBV NDA >= 4 log10 copies/mL, Chronic hepatitis B with cirrhosis ; HBV NDA >= 3 log10 copies/mL
- Serum ALT <= 10 × ULN
- Creatinine clearance >= 70 mL/min
- Haemoglobin >= 8 g/dL
- WBC >= 1,000 /mm3
Exclusion Criteria:
- Decompensated liver disease
- Co-infection with HIV or HCV
- Autoimmune hepatitis rather than chronic hepatitis B
- Subject with serious complication
- Received or have a plan for solid organ or bone marrow transplantation
- Has proximal tubulopathy
- History of hypersensitivity to nucleoside and/or nucleotide analogues
- Evidence of hepatocellular carcinoma by diagnostic imaging at screening and/or serum α-fetoprotein > 50 ng/mL at screening
- History of HCC
- Received any interferon or HB vaccine therapy within 24 weeks prior to initiation
- Received overdose NSAIDs, excluding temporary or topical use, within 7 days prior to initiation
- Received drugs for injection containing glycyrrhizin as the main component within 4 weeks prior to initiation
- Received drugs causing renal impairment, competitors of renal excretion, immunosuppressants, chemotherapeutics and/or corticosteroids within 8 weeks prior to initiation
- Participation in another clinical study within 6 months of study entry or planned participation in another clinical study after entry to this study
- Woman who is pregnant, lactating, possibly pregnant or planning a pregnancy during the study period
- Psychiatry disorder or cognitive disorder that may affect the subject ability to give informed consent or to follow specified study procedures
- History of alcohol or drug abuse
- Any condition or situation that may interfere with the subject's participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GSK548470 300 mg
GSK548470 300 mg tablet is administered orally once daily
|
Blue tablets containing 300 mg of tenofovir disoproxil fumarate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24
Time Frame: Week 24
|
The number of participants with serum hepatitis B virus deoxyribonucleic acid (HBV DNA) level < the lower limit of quantitation (2.1 log10 copies/millilitres[copies/mL]) (i.e., the rate of suppression) at Week 24 was summarized.
Statistical analysis was not provided for the number of participants achieving HBV DNA <2.1 log10 copies/mL (at Week 24).
Missing values observed during the treatment period was imputed by the last observation carried forward (LOCF) method.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96
Time Frame: Week 24, Week 48 and Week 96
|
The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized.
ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment.
The LOCF method was applied for missing values.
|
Week 24, Week 48 and Week 96
|
Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96
Time Frame: Week 24, Week 48 and Week 96
|
The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized.
Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative.
The LOCF method was applied for missing values.
|
Week 24, Week 48 and Week 96
|
Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96
Time Frame: Week 24, Week 48 and Week 96
|
The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized.
Loss of HBsAg is defined as change of detectable HBsAg from positive to negative.
The LOCF method was applied for missing values.
|
Week 24, Week 48 and Week 96
|
Mean Change From Baseline in Serum HBV DNA Level at Week 24, Week 48 and Week 96
Time Frame: Baseline and Week 24, Week 48 and Week 96
|
The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24, Week 48 and Week 96 were assessed (HBV DNA values below the lower limit of quantitation [i.e.
2.1 log10 copies/mL] for the assay were set to the lower limit minus 0.1 [i.e.
2.0 log10 copies/mL]).
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
The Last Observation Carried Forward (LOCF) method was applied for missing values.
|
Baseline and Week 24, Week 48 and Week 96
|
Number of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 48 and Week 96
Time Frame: Week 48 and Week 96
|
The number of participants with serum HBV DNA level < the lower limit of quantitation (2.1 log10 copies/mL) (i.e., the rate of suppression) at Week 48 and Week 96 were summarized.
The LOCF method was applied for missing values.
|
Week 48 and Week 96
|
Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96
Time Frame: Week 24, Week 48 and Week 96
|
The number of participants achieving hepatitis Be antigen (HBeAg)/hepatitis B e antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized.
Seroconversion to HBeAg is defined as change of detectable antibody to HBeAg from negative to positive.
The LOCF method was applied for missing values.
|
Week 24, Week 48 and Week 96
|
Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96
Time Frame: Week 24, Week 48 and Week 96
|
The number of participants with hepatitis B surface antigen (HBsAg)/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized.
HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
The LOCF method was applied for missing values.
|
Week 24, Week 48 and Week 96
|
Number of Participants With Virological Breakthrough and Resistance-related Mutations
Time Frame: Screening, Week 24, Week 48, Week 96 and Virological Breakthrough
|
The number of participants who harbored resistance-related mutations and developed virological breakthrough was summarized.
Virological breakthrough defined as HBV DNA level increase >=1 log10 copies/mL above the treatment nadir were analyzed through end of treatment.
Subjects who achieved the HBV-DNA values below lower limit of quantification (LLQ) (< 2.1 log10 copies/mL) in quantitative analysis at Week 96 were also considered "negative" in drug-resistance without implementation of genotypic analysis.
Lamivudine (LAM), adefovir pivoxil (ADV), and entecavir hydrate (ETV) resistance-related mutations were analyzed at Screening (i.e.
Baseline), Week 24, Week 48 and Week 96 in participants with HBV DNA level above the lower limit of detection.
Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV DNA levels from on-treatment nadir.
The LOCF method was applied for missing values.
|
Screening, Week 24, Week 48, Week 96 and Virological Breakthrough
|
Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96
Time Frame: Baseline, Week 24, Week 48 and Week 96
|
The number of participants achieving each indicated hepatitis B surface antigen (HBsAg) category (HBsAg <80, 80 to 800, 800 to 8000, 8000 to 80000, >=80000) (kilo international unit per liter [KIU/L]) by study visit was summarized.
|
Baseline, Week 24, Week 48 and Week 96
|
Number of Participants Achieving Each Indicated HBcrAg Category at Baseline,Week 24, Week 48 and Week 96
Time Frame: Baseline, Week 24, Week 48 and Week 96
|
The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg <3.0 log10, 3.0 to 4.0 log10, 4.0 to 5.0 log10, 5.0 to 6.0 log10, >=6.0 log10) (kilo units per liter [KU/L]) by study visit was summarized.
The LOCF method was applied for missing values.
|
Baseline, Week 24, Week 48 and Week 96
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
November 17, 2011
First Submitted That Met QC Criteria
November 17, 2011
First Posted (Estimate)
November 21, 2011
Study Record Updates
Last Update Posted (Estimate)
June 22, 2015
Last Update Submitted That Met QC Criteria
June 18, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
Other Study ID Numbers
- 115912
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
Clinical Trials on GSK548470 300 mg tablet
-
GlaxoSmithKlineCompleted
-
Altavant Sciences GmbHCompletedPulmonary Arterial HypertensionUnited States, Spain, United Kingdom, Czechia, Serbia, Canada, Poland, Italy, Bosnia and Herzegovina, Austria, Germany, Belgium, Bulgaria, France, Latvia, Moldova, Republic of, Ukraine
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
Novartis PharmaceuticalsCompletedHypertensionSweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
-
Biota Pharmaceuticals, Inc.Completed
-
VM Oncology, LLCRecruitingSarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Any Solid Tumors Progressed After a Prior ImmunotherapyUnited States, Puerto Rico
-
Orion Corporation, Orion PharmaBayerCompleted
-
McGill University Health Centre/Research Institute...RecruitingESRD | CKD Stage 4 | CKD Stage 5Canada
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
Future MedicineFuturemedicine AustraliaRecruitingOcular HypertensionAustralia